Stay updated on Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedSite revision updated from v3.4.1 to v3.4.2; no changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision: v3.4.1 was added and replaced the previous v3.4.0, representing a metadata/version update without changes to the study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded a glossary display and updated QC metadata labels (e.g., Last Update Submitted that Met QC Criteria) along with a new revision note (v3.4.0), replacing prior wording (v3.3.4).SummaryDifference0.2%

- Check62 days agoChange DetectedThe page's revision metadata was updated from v3.3.3 to v3.3.4, with no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a Locations section listing California and Tennessee study sites; removed the separate California Locations and Tennessee Locations entries. Revision: v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.